Michael acceptor containing drugs are a novel class of 5-lipoxygenase inhibitor targeting the surface cysteines C416 and C418.
Maucher IV, Rühl M, Kretschmer SB, Hofmann B, Kühn B, Fettel J, Vogel A, Flügel KT, Manolikakes G, Hellmuth N, Häfner AK, Golghalyani V, Ball AK, Piesche M, Matrone C, Geisslinger G, Parnham MJ, Karas M, Steinhilber D, Roos J, Maier TJ.
Maucher IV, et al. Among authors: ball ak.
Biochem Pharmacol. 2017 Feb 1;125:55-74. doi: 10.1016/j.bcp.2016.11.004. Epub 2016 Nov 4.
Biochem Pharmacol. 2017.
PMID: 27823964